Radiochemist in CMC Development

Y-mAbs Therapeutics is expanding its activities within radiochemistry, and we are therefore looking for a candidate with a strong scientific knowledge within radiochemistry for therapeutic use.

The position will be part of our CMC development team and will be an integrated part of our development activities for our radiolabeled product candidates.

The development activities will both be directly linked to our CMC projects, and also general development activities, which partly will be conducted in nearby radioisotope laboratories.

Preferred qualifications:

- In-depth knowledge in radiochemistry
  - Synthesis, purification and analysis of radiolabeled biomolecules and small molecules with different therapeutic radioisotopes, preferable:
    - Iodine-131
    - Lutetium-177
    - Actinium-225
  - Quality Control of radiopharmaceutical products
    - Characterization with different methods (HPLC, iTLC, Gamma spectrometry)
    - Method development

- Development of automatized radiolabeling
  - Radiolabeling of biomolecules and small molecules with synthesizers
  - Kit-type development for automatized radiolabeling of biomolecules and small molecules

- CMC/GMP experience
  - Knowledge in GMP requirements for radiolabeled drug products
  - Knowledge on regulatory requirements for CMC documentations

For more details about the job or our company, please contact Tore Søderblom, Senior Director, CMC Development on +45 5388 0988. Please note that all applications must be submitted in English and will be treated confidentially.

You can apply for the position by sending an email to HR@ymabs.com. Please mark your application with Job ID no. 1052.

Y-mAbs Therapeutics A/S is a Danish affiliate of Y-mAbs Therapeutics Inc., which is located in Hørsholm, Denmark. Our mission is to discover, develop and deliver novel antibody therapeutics for the treatment of both pediatric and adult cancer patients.

Please access the company web site www.ymabs.com for more information regarding the company and our development projects.